Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies
Publication
, Conference
Al-Rohil, R; Rand, JV; Jones, DM; Lee, HJ; Sheehan, CE; Otto, G; Palmer, G; Yelensky, R; Lipson, D; White, E; Balasubramanian, S; Garcia, L ...
Published in: LABORATORY INVESTIGATION
February 1, 2013
Duke Scholars
Published In
LABORATORY INVESTIGATION
ISSN
0023-6837
Publication Date
February 1, 2013
Volume
93
Start / End Page
397A / 397A
Location
Baltimore, MD
Publisher
NATURE PUBLISHING GROUP
Conference Name
102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)
Related Subject Headings
- Pathology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G., … Ross, J. S. (2013). Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. In LABORATORY INVESTIGATION (Vol. 93, pp. 397A-397A). Baltimore, MD: NATURE PUBLISHING GROUP.
Al-Rohil, R., J. V. Rand, D. M. Jones, H. J. Lee, C. E. Sheehan, G. Otto, G. Palmer, et al. “Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies.” In LABORATORY INVESTIGATION, 93:397A-397A. NATURE PUBLISHING GROUP, 2013.
Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto G, et al. Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. In: LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP; 2013. p. 397A-397A.
Al-Rohil, R., et al. “Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies.” LABORATORY INVESTIGATION, vol. 93, NATURE PUBLISHING GROUP, 2013, pp. 397A-397A.
Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto G, Palmer G, Yelensky R, Lipson D, White E, Balasubramanian S, Garcia L, Mahoney K, Richards T, Terzic S, Banning V, Curran J, Downing S, Miller V, Stephens P, Ross JS. Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP; 2013. p. 397A-397A.
Published In
LABORATORY INVESTIGATION
ISSN
0023-6837
Publication Date
February 1, 2013
Volume
93
Start / End Page
397A / 397A
Location
Baltimore, MD
Publisher
NATURE PUBLISHING GROUP
Conference Name
102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)
Related Subject Headings
- Pathology
- 3202 Clinical sciences
- 1103 Clinical Sciences